Develops drugs for rare diseases.
Jun 2026Revenue $1.01B/yrExpenses $883M/yr
Reached break-even Apr 2026
Figures by year
When did PTC Therapeutics become profitable?
Its revenue passed its expenses in Apr 2026. In the 12 months to Jun 2026, revenue was $1.01B and expenses $883M.
| Fiscal year to | Revenue | Expenses | Operating profit |
|---|---|---|---|
| Dec 2025 | $1.73B | $864M | $867M |
| Dec 2024 | $807M | $1.11B | −$303M |
| Dec 2023 | $938M | $1.38B | −$440M |
| Dec 2022 | $699M | $1.15B | −$447M |
| Dec 2021 | $539M | $913M | −$374M |
| Dec 2020 | $381M | $813M | −$432M |
| Dec 2019 | $307M | $548M | −$241M |
| Dec 2018 | $265M | $380M | −$116M |
| Dec 2017 | $194M | $259M | −$64.3M |
| Dec 2016 | $82.7M | $215M | −$132M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.